[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials",
    "summary": "On Sunday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced multiple program updates, including: In December, the FDA approved Vertex's Alyftrek (vanzacaftor / tezacaftor / deutivacaftor), a once-daily triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. Vertex raised its CF patient estimates",
    "url": "https://finnhub.io/api/news?id=6c2dfe9cef34eaa7bb107d6e376942dd1708f4e4135ab8b714302352868e9951",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736884029,
      "headline": "Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials",
      "id": 132421526,
      "image": "https://media.zenfs.com/en/Benzinga/935989c9db6593ae20b96f8ade791831",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "On Sunday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced multiple program updates, including: In December, the FDA approved Vertex's Alyftrek (vanzacaftor / tezacaftor / deutivacaftor), a once-daily triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. Vertex raised its CF patient estimates",
      "url": "https://finnhub.io/api/news?id=6c2dfe9cef34eaa7bb107d6e376942dd1708f4e4135ab8b714302352868e9951"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Therapeutics: The Pain Comes With The Territory For Suzetrigine",
    "summary": "I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is under investigation as a pain relief medication.",
    "url": "https://finnhub.io/api/news?id=f344bb58bcf671a67adde18f76ed7793db4f34c1170da5b08d9f9a109f115637",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736820420,
      "headline": "Vertex Therapeutics: The Pain Comes With The Territory For Suzetrigine",
      "id": 132391720,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/909908830/image_909908830.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is under investigation as a pain relief medication.",
      "url": "https://finnhub.io/api/news?id=f344bb58bcf671a67adde18f76ed7793db4f34c1170da5b08d9f9a109f115637"
    }
  }
]